Drug Insights

Making the Most Out of Synapse: Searching for Levetiracetam

20 March 2024
2 min read

Levetiracetam, a diminutive molecular entity, has been engineered to hone in on the synaptic vesicle protein 2A (SV2A) as a modulation target. This pharmaceutical compound was the fruit of the laborious efforts of UCB SA, and in the month of November in 1999, it was granted its maiden approval. In the realm of medicine, Levetiracetam is widely employed as an anticonvulsant agent for the management of epilepsy. This compound has been known to exhibit anticonvulsant properties by diminishing the frequency and intensity of seizures in patients. Levetiracetam's modulatory effect arises from its binding to the SV2A protein, which assumes a role in the regulation of neurotransmitter release in the brain. Moreover, the favorable side-effect profile of this compound and its marked tolerance by patients make it a frequent choice for the management of epilepsy. Click on the image below to begin the exploration journey of Levetiracetam through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Results for Nuvectis Pharma's NXP800 in ARID1a-Altered Ovarian Cancer
Latest Hotspot
3 min read
Promising Results for Nuvectis Pharma's NXP800 in ARID1a-Altered Ovarian Cancer
20 March 2024
Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.
Read →
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
Hot Spotlight
7 min read
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
19 March 2024
On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.
Read →
Who should not take semaglutide?
Knowledge Base
2 min read
Who should not take semaglutide?
19 March 2024
Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)
Read →
Synapse Simplified: How to Find Ketoconazole Information
Drug Insights
2 min read
Synapse Simplified: How to Find Ketoconazole Information
19 March 2024
Ketoconazole, a diminutive molecular compound, functions as an inhibitor of CYP51A1.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.